AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merus Announces Positive Phase 2 Data for Petosemtamab in mCRC
ByAinvest
Saturday, Oct 25, 2025 5:27 am ET1min read
Merus has announced preliminary clinical data from a phase 2 study of bispecific antibody petosemtamab in combination with standard treatment FOLFOX/FOLFIRI in first-line (1L) and second-line (2L) metastatic colorectal cancer (mCRC), as well as petosemtamab monotherapy in third-line (3L+) mCRC. The data showed a 100% response rate in 1L link-sided mCRC and a 62% response rate in 2L link- and right-sided mCRC. The study is ongoing, and updated data will be presented at the American Association for Cancer Research (AACR) annual meeting.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet